AstraZeneca Pharma India Ltd has received clearance from the Central Drugs Standard
Control Organisation (CSDCO) to import, sell, and distribute its cancer treatment drug,
Lynparza (Olaparib). The medication, available in 100 mg and 150 mg film-coated tablets, is
specifically indicated for use in combination with Durvalumab for maintaining treatment in
adults with advanced or recurrent endometrial cancer whose disease has remained stable
following first-line treatment with Durvalumab and platinum-based chemotherapy.
This regulatory nod allows AstraZeneca to proceed with the drug’s launch in India, pending
additional statutory approvals. Lynparza represents a critical addition to cancer treatment
options, reflecting advancements in personalized medicine and targeted therapies for complex
diseases.
Menu
